Research Analysts Issue Forecasts for EPRX FY2025 Earnings

Key Points

• Cantor Fitzgerald has downgraded the FY2025 earnings forecast for Eupraxia Pharmaceuticals to ($0.70) per share, down from a previous estimate of ($0.63).
• The company's latest quarterly report showed a loss of ($0.26) per share, which was below the analysts' consensus estimate of ($0.21).
• Eupraxia Pharmaceuticals currently has an average analyst rating of "Buy" with a consensus price target of $11.00.

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Free Report) - Stock analysts at Cantor Fitzgerald decreased their FY2025 EPS estimates for Eupraxia Pharmaceuticals in a research report issued to clients and investors on Thursday, August 14th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($0.70) per share for the year, down from their previous forecast of ($0.63). Cantor Fitzgerald has a "Overweight" rating and a $11.00 price target on the stock. The consensus estimate for Eupraxia Pharmaceuticals' current full-year earnings is ($0.67) per share. Cantor Fitzgerald also issued estimates for Eupraxia Pharmaceuticals' FY2026 earnings at ($0.67) EPS.

Eupraxia Pharmaceuticals (NASDAQ:EPRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.05).

Several other research analysts have also recently issued reports on the stock. Canaccord Genuity Group started coverage on shares of Eupraxia Pharmaceuticals in a report on Monday, June 16th. They set a "speculative buy" rating for the company. HC Wainwright reissued a "buy" rating and set a $12.00 price objective on shares of Eupraxia Pharmaceuticals in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $11.00.

Eupraxia Pharmaceuticals Stock Up 1.5%

NASDAQ EPRX traded up $0.08 during trading hours on Monday, hitting $5.28. 3,916 shares of the stock were exchanged, compared to its average volume of 11,043. The company has a market cap of $189.87 million, a price-to-earnings ratio of -6.21 and a beta of 1.50. Eupraxia Pharmaceuticals has a 12-month low of $2.20 and a 12-month high of $6.20. The stock has a 50-day moving average of $5.21 and a 200 day moving average of $4.20.

Institutional Trading of Eupraxia Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can boosted its holdings in Eupraxia Pharmaceuticals by 15.2% during the fourth quarter. Bank of Montreal Can now owns 56,750 shares of the company's stock worth $178,000 after buying an additional 7,500 shares in the last quarter. Millennium Management LLC purchased a new position in Eupraxia Pharmaceuticals during the 4th quarter valued at about $31,000. Bank of America Corp DE increased its holdings in Eupraxia Pharmaceuticals by 402.4% during the 2nd quarter. Bank of America Corp DE now owns 12,559 shares of the company's stock valued at $72,000 after acquiring an additional 10,059 shares in the last quarter. Quadrature Capital Ltd purchased a new position in Eupraxia Pharmaceuticals during the 2nd quarter valued at about $61,000. Finally, Raymond James Financial Inc. purchased a new position in Eupraxia Pharmaceuticals during the 4th quarter valued at about $37,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.